2021 Global Biopharma R&D Productivity And Growth Ranking
Including First Ever Small- To Mid-Size Pharma Ranking
Executive Summary
A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.
You may also be interested in...
2022 Global Biopharma R&D Productivity And Growth Ranking
The R&D productivity of the top 30 largest biopharma companies decreased slightly from 2021 to 2022 and the sector saw the lowest number of FDA approvals in the past 10 years.
Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
2020 Global Biopharma R&D Productivity And Growth Ranking
The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.